|
SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.
Number of employees : 890 people.
|
|
| 2020 | 2021 | Delta | Pharmaceuticals | 2 155.88 | 100% | 3 035.29 | 100% | +40.79% |
HKD in Million |
|
|
| 2020 | 2021 | Delta | China | 2 061.03 | 95.6% | 2 967.21 | 97.8% | +43.97% |
Others | 94.84 | 4.4% | 68.08 | 2.2% | -28.22% |
HKD in Million |
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
695,524,226 |
387,174,693 |
55.7% |
10,189,963 |
1.5% |
55.7% |
|
|
Name | Equities | % | GL Capital Group | 195,104,060 |
28.5% | CDH Investments Management (Hong Kong) Ltd. | 106,536,790 |
15.5% | Ascendent Capital Partners (China) Ltd. | 103,497,710 |
15.1% | Bank of China Limited | 84,523,130 |
12.3% | Wei Hang Zhu | 53,473,820 |
7.80% | Shanghai Pharmaceuticals Holding Co., Ltd | 12,368,500 |
1.80% | Bosera Capital Management Co. Ltd. | 12,368,500 |
1.80% | Hong Zhao | 12,179,690 |
1.78% | Juli Information Consulting (Beijing) Co. Ltd. | 11,979,690 |
1.75% | China Post & Capital Global Asset Management Ltd. | 8,245,500 |
1.20% |
|
|
|
Sector Biopharmaceuticals
| | | |
 | CSL LIMITED | -4.63% | 92 449 |
 | SAMSUNG BIOLOGICS CO.,LTD. | -14.73% | 42 728 |
 | BIOGEN INC. | -17.31% | 29 053 |
 | WUXI BIOLOGICS (CAYMAN) INC. | -42.68% | 28 509 |
 | CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. | -22.41% | 22 801 |
 | UCB | -11.67% | 17 445 |
 | BIOMARIN PHARMACEUTICAL INC. | -12.48% | 14 304 |
 | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. | 1.72% | 13 909 |
 | GRIFOLS, S.A. | 16.33% | 11 948 |
 | WALVAX BIOTECHNOLOGY CO., LTD. | -11.07% | 11 799 |
 | BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED | -19.48% | 8 867 |
 | SK BIOSCIENCE CO.,LTD. | -44.44% | 7 483 |
 | SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. | -33.02% | 6 813 |
 | CELLTRION HEALTHCARE CO., LTD. | -32.67% | 6 557 |
 | SWEDISH ORPHAN BIOVITRUM AB (PUBL) | 17.29% | 6 354 |
 | HUALAN BIOLOGICAL ENGINEERING INC. | -42.79% | 4 483 |
 | BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. | -26.76% | 4 293 |
 | APELLIS PHARMACEUTICALS, INC. | -17.85% | 4 137 |
 | CANSINO BIOLOGICS INC. | -59.55% | 3 819 |
 | INNOVENT BIOLOGICS, INC. | -59.38% | 3 661 |
Connections : SciClone Pharmaceuticals (Holdings) Limited
|